{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:26:44Z","timestamp":1785882404479,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"DOI":"10.7759\/cureus.74141","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:59:39Z","timestamp":1732193979000},"source":"Crossref","is-referenced-by-count":9,"title":["Innovative mRNA Vaccine Approaches in Targeting Atherosclerosis: A New Era in Cardiovascular Therapy"],"prefix":"10.7759","author":[{"given":"Rahul","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri","family":"Krishnaperumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Vellapandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. fact sheets - cardiovascular diseases. (2021). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68650","article-title":"Unraveling the nexus between ambient air pollutants and cardiovascular morbidity: mechanistic insights and therapeutic horizons","volume":"16","author":"Kumar V","year":"2024","unstructured":"Kumar V, Vellapandian C. Unraveling the nexus between ambient air pollutants and cardiovascular morbidity: mechanistic insights and therapeutic horizons. Cureus. 2024, 16:e68650. 10.7759\/cureus.68650","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810166","article-title":"Development of mRNA lipid nanoparticles: targeting and therapeutic aspects","volume":"25","author":"Liu Y","year":"2024","unstructured":"Liu Y, Huang Y, He G, Guo C, Dong J, Wu L. Development of mRNA lipid nanoparticles: targeting and therapeutic aspects. Int J Mol Sci. 2024, 25:10.3390\/ijms251810166","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c00958","article-title":"Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis","volume":"17","author":"Gao M","year":"2023","unstructured":"Gao M, Tang M, Ho W, et al.. Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis. ACS Nano. 2023, 17:17721-39. 10.1021\/acsnano.3c00958","journal-title":"ACS Nano"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman S","year":"2022","unstructured":"Jebari-Benslaiman S, Galicia-Garc\u00eda U, Larrea-Sebal A, et al.. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022, 23:10.3390\/ijms23063346","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany S","year":"2019","unstructured":"Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019, 20:10.3390\/ijms20236008","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-016-0186-5","article-title":"The importance of antioxidants which play the role in cellular response against oxidative\/nitrosative stress: current state","volume":"15","author":"Kurutas EB","year":"2016","unstructured":"Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative\/nitrosative stress: current state. Nutr J. 2016, 15:71. 10.1186\/s12937-016-0186-5","journal-title":"Nutr J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-015-0463-z","article-title":"Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"110","author":"Schulz R","year":"2015","unstructured":"Schulz R, Schl\u00fcter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res Cardiol. 2015, 110:4. 10.1007\/s00395-015-0463-z","journal-title":"Basic Res Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake T","year":"2012","unstructured":"Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012, 9:1319-30. 10.4161\/rna.22269","journal-title":"RNA Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/IN9.0000000000000017","article-title":"Mechanisms of continual efferocytosis by macrophages and its role in mitigating atherosclerosis","volume":"5","author":"Kumar D","year":"2023","unstructured":"Kumar D, Pandit R, Yurdagul A Jr. Mechanisms of continual efferocytosis by macrophages and its role in mitigating atherosclerosis. Immunometabolism (Cobham). 2023, 5:e00017. 10.1097\/IN9.0000000000000017","journal-title":"Immunometabolism (Cobham)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone MA Jr","year":"2016","unstructured":"Gimbrone MA Jr, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016, 118:620-36. 10.1161\/CIRCRESAHA.115.306301","journal-title":"Circ Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote V","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023, 24:10.3390\/ijms24032700","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.22038\/IJBMS.2024.74352.16148","article-title":"Preclinical models of atherosclerosis: an overview","volume":"27","author":"Arya P","year":"2024","unstructured":"Arya P, Sharma V, Thapliyal S, Sagar R, Singh P. Preclinical models of atherosclerosis: an overview. Iran J Basic Med Sci. 2024, 27:535-42. 10.22038\/IJBMS.2024.74352.16148","journal-title":"Iran J Basic Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong P","year":"2022","unstructured":"Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022, 7:131. 10.1038\/s41392-022-00955-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang G","year":"2023","unstructured":"Zhang G, Tang T, Chen Y, Huang X, Liang T. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther. 2023, 8:365. 10.1038\/s41392-023-01579-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20209557","article-title":"Animal models of human atherosclerosis: current progress","volume":"53","author":"Poznyak AV","year":"2020","unstructured":"Poznyak AV, Silaeva YY, Orekhov AN, Deykin AV. Animal models of human atherosclerosis: current progress. Braz J Med Biol Res. 2020, 53:e9557. 10.1590\/1414-431x20209557","journal-title":"Braz J Med Biol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00835-w","article-title":"Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review","volume":"43","author":"Zhang FS","year":"2022","unstructured":"Zhang FS, He QZ, Qin CH, Little PJ, Weng JP, Xu SW. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin. 2022, 43:2173-90. 10.1038\/s41401-021-00835-w","journal-title":"Acta Pharmacol Sin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106738","article-title":"Lipid lowering combination therapy: from prevention to atherosclerosis plaque treatment","volume":"190","author":"Masana L","year":"2023","unstructured":"Masana L, Plana N, Andreychuk N, Ibarretxe D. Lipid lowering combination therapy: from prevention to atherosclerosis plaque treatment. Pharmacol Res. 2023, 190:106738. 10.1016\/j.phrs.2023.106738","journal-title":"Pharmacol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46040220","article-title":"Inflammasome molecular insights in autoimmune diseases","volume":"46","author":"Neam\u021bu M","year":"2024","unstructured":"Neam\u021bu M, Bild V, Vasincu A, et al.. Inflammasome molecular insights in autoimmune diseases. Curr Issues Mol Biol. 2024, 46:3502-32. 10.3390\/cimb46040220","journal-title":"Curr Issues Mol Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang YS","year":"2023","unstructured":"Wang YS, Kumari M, Chen GH, Hong MH, Yuan JP, Tsai JL, Wu HC. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J Biomed Sci. 2023, 30:84. 10.1186\/s12929-023-00977-5","journal-title":"J Biomed Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020503","article-title":"Proprotein convertase subtilisin\/kexin 9 as a modifier of lipid metabolism in atherosclerosis","volume":"11","author":"Poznyak AV","year":"2023","unstructured":"Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Gutyrchik NA, Orekhov AN. Proprotein convertase subtilisin\/kexin 9 as a modifier of lipid metabolism in atherosclerosis. Biomedicines. 2023, 11:10.3390\/biomedicines11020503","journal-title":"Biomedicines"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7205241","article-title":"Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine","volume":"2022","author":"Sharma A","year":"2022","unstructured":"Sharma A, Virmani T, Pathak V, Sharma A, Pathak K, Kumar G, Pathak D. Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine. Biomed Res Int. 2022, 2022:7205241. 10.1155\/2022\/7205241","journal-title":"Biomed Res Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313227-innovative-mrna-vaccine-approaches-in-targeting-atherosclerosis-a-new-era-in-cardiovascular-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:59:42Z","timestamp":1732193982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313227-innovative-mrna-vaccine-approaches-in-targeting-atherosclerosis-a-new-era-in-cardiovascular-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.74141","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}